GLP-1 drugs emerge as multi-organ protectors far beyond blood sugar control
A new narrative review argues that GLP-1 receptor agonists should be repositioned as foundational cardio-renal-metabolic protectors, with trial evidence extending ...
Tag: FLOW trial
